CL2011001364A1 - Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv). - Google Patents

Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv).

Info

Publication number
CL2011001364A1
CL2011001364A1 CL2011001364A CL2011001364A CL2011001364A1 CL 2011001364 A1 CL2011001364 A1 CL 2011001364A1 CL 2011001364 A CL2011001364 A CL 2011001364A CL 2011001364 A CL2011001364 A CL 2011001364A CL 2011001364 A1 CL2011001364 A1 CL 2011001364A1
Authority
CL
Chile
Prior art keywords
hepatitis
hcv
compound
treatment
cyclopropyl
Prior art date
Application number
CL2011001364A
Other languages
English (en)
Inventor
Tim Hugo Maria Jonckers
Pierre Jena Marie Bernardvan Hoff Steven Maurice Paula Raboisson
Leen Anna Mari Vandekerckhove
Original Assignee
Centocor Ortho Biotech Products L P Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Products L P Medivir Ab filed Critical Centocor Ortho Biotech Products L P Medivir Ab
Publication of CL2011001364A1 publication Critical patent/CL2011001364A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos nucleótidos inhibidores de la polimerasa del virus de hepatitis C; composición farmacéutica que los comprende; y uso del compuesto para el tratamiento de hepatitis C (HCV).
CL2011001364A 2008-12-08 2011-06-07 Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv). CL2011001364A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08171006 2008-12-08

Publications (1)

Publication Number Publication Date
CL2011001364A1 true CL2011001364A1 (es) 2011-09-23

Family

ID=40852521

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001364A CL2011001364A1 (es) 2008-12-08 2011-06-07 Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv).

Country Status (21)

Country Link
US (1) US8399429B2 (es)
EP (1) EP2373671B1 (es)
JP (1) JP5683480B2 (es)
KR (1) KR20110104000A (es)
CN (1) CN102256991B (es)
AP (1) AP2011005717A0 (es)
AR (1) AR074504A1 (es)
AU (1) AU2009326125B2 (es)
BR (1) BRPI0922681A2 (es)
CA (1) CA2745523C (es)
CL (1) CL2011001364A1 (es)
EA (1) EA020244B1 (es)
ES (1) ES2525007T3 (es)
IL (1) IL212897A (es)
MX (1) MX2011006023A (es)
PA (1) PA8852101A1 (es)
SG (1) SG171973A1 (es)
TW (1) TW201036989A (es)
UY (1) UY32308A (es)
WO (1) WO2010066699A1 (es)
ZA (1) ZA201104231B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
SI3150616T1 (sl) * 2012-11-16 2017-08-31 University College Cardiff Consultants Limited Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
AU2014225052B2 (en) * 2013-03-08 2016-11-10 Nanjing Sanhome Pharmaceutical Co., Ltd. Novel nucleoside phosphoramidate compound and use thereof
CN103848876B (zh) * 2013-03-25 2016-05-11 安徽贝克联合制药有限公司 一种核苷磷酰胺前药及其制备方法和其应用
US9447132B2 (en) 2013-04-12 2016-09-20 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
CN105348342B (zh) * 2014-09-30 2018-09-21 南京正大天晴制药有限公司 核苷氨基磷酸酯化合物及药物组合物和用途
WO2016073756A1 (en) * 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
CN105801646B (zh) * 2014-12-31 2019-08-16 浙江大德药业集团有限公司 炔基取代的核苷氨基磷酸酯
WO2016134053A1 (en) * 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
JP6743135B2 (ja) 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
CA2170020C (en) 1992-12-29 2005-08-02 Dale J. Kempf Retroviral protease inhibiting compounds
US20010021509A1 (en) * 1997-10-23 2001-09-13 Sathe Ganesh Madhusudan cDNA clone HNEAA81 that encodes a human 7-transmembrane receptor
TW200500375A (en) * 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
CN102174038A (zh) * 2003-02-19 2011-09-07 耶鲁大学 用于治疗病毒感染的抗病毒核苷
EA014685B1 (ru) * 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
CA2600886A1 (en) * 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
AP2009004812A0 (en) 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor

Also Published As

Publication number Publication date
CA2745523A1 (en) 2010-06-17
JP2012510980A (ja) 2012-05-17
WO2010066699A1 (en) 2010-06-17
ES2525007T3 (es) 2014-12-17
IL212897A0 (en) 2011-07-31
MX2011006023A (es) 2011-06-28
AP2011005717A0 (en) 2011-06-30
AR074504A1 (es) 2011-01-19
CN102256991B (zh) 2015-08-12
EP2373671A1 (en) 2011-10-12
CN102256991A (zh) 2011-11-23
UY32308A (es) 2010-06-30
AU2009326125B2 (en) 2015-03-12
SG171973A1 (en) 2011-07-28
CA2745523C (en) 2017-07-04
JP5683480B2 (ja) 2015-03-11
ZA201104231B (en) 2012-11-28
TW201036989A (en) 2010-10-16
AU2009326125A1 (en) 2010-06-17
PA8852101A1 (es) 2010-07-27
IL212897A (en) 2013-12-31
EA020244B1 (ru) 2014-09-30
EA201170780A1 (ru) 2011-12-30
EP2373671B1 (en) 2014-09-10
KR20110104000A (ko) 2011-09-21
BRPI0922681A2 (pt) 2016-01-05
US8399429B2 (en) 2013-03-19
US20110230436A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
CL2011001364A1 (es) Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv).
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2011000136A1 (es) Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c.
BRPI0922366B8 (pt) composto, composição farmacêutica e uso de um composto
CR10136A (es) Nucleósidos antivirales
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
EA201270555A1 (ru) Комбинации ингибиторов вируса гепатита с
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2013001141A1 (es) Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
CL2010001634A1 (es) Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.
CL2007003250A1 (es) Compuestos derivados de isoquinolina, inhibidores del virus de hepatitis c; composicion farmaceutica; y uso para el tratamiento de una infeccion por vhc.
CL2008001005A1 (es) Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
CL2011001224A1 (es) Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c.
ATE505475T1 (de) Nukleosidderivate als inhibitoren viraler polymerasen
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
CL2014001599A1 (es) Compuestos derivados de nucleosidos sustituidos en 4’-azido, 3’-fluoro o sus sales, como inhibidores de la replicacion del rna del vhc; composicion farmaceutica que los comprende; y su uso para el tratamiento o la profilaxis de la infeccion por el virus de la hepatitis c (vhc).
BR112013002729A2 (pt) inibidores de vírus de hepatite c
CR20110605A (es) Compuestos heterocíclicos antivirales
CL2008002291A1 (es) Compuestos derivados del acido 4-fluor-benzoico, inhibidores de la polimerasa hcv, composicion farmaceutica, kit farmaceutico y su uso para el tratamiento de una infeccion viral por hepatitis c.
PL2209789T3 (pl) Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV
UY30545A1 (es) Derivados sustituidos del acido acilamino-benzoico, composiciones que los contienen y aplicaciones
BR112012014299A2 (pt) composto de antivírus heterocíclicos